Know Labs
KNW
Market cap $24.8M

0.2295 USD

+0.0102

4.65%

At close Nov 19, 4:00 PM EST

1 day

4.65%

5 days

-5.17%

1 month

17.69%

3 months

-25.94%

6 months

-65.35%

Year to date

-57.06%

1 year

-47.84%

5 years

-89.07%

10 years

-89.07%

About: Know Labs Inc is a medical diagnostic. The company is focused on the development, marketing, and sales of proprietary technologies that are capable of uniquely identifying or authenticating almost any substance or material using electromagnetic energy to record, detect, and identify the signature of the substance or material known as Bio-RFID and ChromaID technologies. It is developing a wearable device that will measure blood glucose without fingersticks or microneedles.

Employees: 15

Industrials Measuring & Controlling Devices

0

Funds holding %

of 6,743 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 31 [Q2] → 31 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

1.97% less ownership

Funds ownership: 5.5% [Q2] → 3.53% (-1.97%) [Q3]

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

44% less capital invested

Capital invested by funds: $1.93M [Q2] → $1.09M (-$843K) [Q3]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for KNW.

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about KNW published over the past 30 days

Know Labs Provides Overview of FY2024 10-K Annual Report

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive diagnostics technology released this morning an overview of its Form 10-K annual report for its fiscal year ending September 30, 2024, and provided reassurance regarding its progress over the past year, its plans and the state of its financial stability in light of its auditor required going concern opinion. Know Labs (the “Company”) issued a press release on November 15, 2024, regarding the rece.

Know Labs Provides Overview of FY2024 10-K Annual Report

Know Labs, Inc. Announces Receipt of Audit Opinion with Going Concern Explanation

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), leading developer of non-invasive diagnostics technology, today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended September 30, 2024, which was filed on November 14, 2024 with the Securities and Exchange Commission, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company.

Know Labs, Inc. Announces Receipt of Audit Opinion with Going Concern Explanation

Know Labs, Inc. Reports Fourth Quarter and Fiscal Year 2024 Results

SEATTLE--(BUSINESS WIRE)--Know Labs, an emerging developer of non-invasive medical diagnostic technology, reported financial results for the Q4 and fiscal year of 2024.

Know Labs, Inc. Reports Fourth Quarter and Fiscal Year 2024 Results

Know Labs Announces Expanded Technology Leadership in its Executive Team

SEATTLE--(BUSINESS WIRE)--Know Labs Announces Expanded Technology Leadership in its Executive Team; Acceleration of Platform Development to Secure Strategic Partnerships.

Know Labs Announces Expanded Technology Leadership in its Executive Team

Know Labs Sensor Technology in Steering Wheels Could Curb Impaired Driving

SEATTLE--(BUSINESS WIRE)--Know Labs Sensor Technology in Steering Wheels Could Curb Impaired Driving. Know Labs Retains Stanbridge Group to Secure Automotive JV Partnerships.

Know Labs Sensor Technology in Steering Wheels Could Curb Impaired Driving

Know Labs Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

SEATTLE--(BUSINESS WIRE)--Know Labs Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards. A Plan for Compliance has been undertaken.

Know Labs Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Know Labs, Inc. (KNW) Q3 2024 Earnings Call Transcript

Know Labs, Inc. (NYSE:KNW ) Q3 2024 Results Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Ron Erickson - Chairman and Chief Executive Officer Peter Conley - Chief Financial Officer and Senior Vice President, IP Conference Call Participants Operator Greetings. Welcome to Know Labs's Third Quarter 2024 Earnings Conference Call.

Know Labs, Inc. (KNW) Q3 2024 Earnings Call Transcript

Know Labs, Inc. Reports Third Quarter FY 2024 Results

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter of the fiscal year 2024 ended June 30, 2024. Financial Highlights: In Q3 FY 2024, Know Labs reported a net loss of $4.10 million dollars, compared to a net loss of $3.60 million dollars in Q3 FY 2023, an increase in net loss of 13.9%. This translates to earnings per share of a loss of $0.05, better than the prio.

Know Labs, Inc. Reports Third Quarter FY 2024 Results

Know Labs, Inc. Announces Closing of $3.445 Million Public Offering

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostics technology, today announced the successful closing of its previously announced underwritten public offering of 13,250,000 units at a public offering price of $0.26 per unit, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock at an initial exercise price of $0.26, and the partial exercise of the underwriters' opt.

Know Labs, Inc. Announces Closing of $3.445 Million Public Offering

Know Labs, Inc. Announces Pricing of $3.445 Million Public Offering

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW) (the “Company”), a leading developer of non-invasive medical diagnostic technology, today announced the pricing of a firm commitment underwritten public offering of 13,250,000 units at a public offering price of $0.26 per unit, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock at an initial exercise price of $0.26 (the "Offering"). The aggregate gross proceeds from t.

Know Labs, Inc. Announces Pricing of $3.445 Million Public Offering

See News Rankings

Charts implemented using Lightweight Charts™